All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study
of First-line Carboplatin and Paclitaxel in Combination with Durvalumab,
Followed by Maintenance Durvalumab with or without Olaparib in Patients
with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
of First-line Carboplatin and Paclitaxel in Combination with Durvalumab,
Followed by Maintenance Durvalumab with or without Olaparib in Patients
with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)